Pancreatic Neoplasm
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Pancreatic Neoplasm is a moderately active landscape with 47 programs across 26 companies. The most active players are Kura Oncology, Inc., EMD Serono Research & Development Institute, Inc., Bristol-Myers Squibb. 19 therapies are approved with 4 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Kura Oncology, Inc.
1 program
EMD Serono Research & Development Institute, Inc.
1 program
Bristol-Myers Squibb
1 program
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
1 program
Shanghai Pharmaceuticals Holding Co., Ltd
1 program
Innovent Biologics (Suzhou) Co. Ltd.
1 program
Pipeline
Programs by Phase
Analysis
Modality Breakdown
74%
Small molecule
35 of 47 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 47 classified programs, each share of the total. Modality classified for 100% of 47 pipeline programs.
Analysis
Trial Status
3
clinical trials
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)